CPIX : Summary for Cumberland Pharmaceuticals Inc. - Yahoo Finance

U.S. Markets closed

Cumberland Pharmaceuticals Inc. (CPIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.71-0.07 (-1.21%)
At close: 4:00PM EST
People also watch
CRMECORTBIODALIMCDXS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.78
Open5.72
Bid0.00 x
Ask12.00 x 1200
Day's Range5.53 - 5.77
52 Week Range4.20 - 6.73
Volume11,718
Avg. Volume21,604
Market Cap92.39M
Beta0.69
PE Ratio (TTM)-1,903.33
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire17 days ago

    Caldolor® Pediatric Fever Study Published Supporting Its Efficacy, Safety And Pharmacokinetics

    NASHVILLE, Tenn., Feb. 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) today announced the publication of a multicenter clinical study demonstrating that Caldolor® (ibuprofen) Injection delivered significant fever reduction in hospitalized children. This study, which adds to the growing body of literature supporting Caldolor, evaluated the efficacy and safety of intravenous ibuprofen in pediatric patients, six months and older, with fever. This pivotal data supported the FDA approval of Caldolor for use in this pediatric patient population.

  • PR Newswire25 days ago

    U.S. Court Of Appeals Affirms Cumberland Pharmaceuticals' Victory In Patent Litigation Case

    NASHVILLE, Tenn., Jan. 30, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced that on January 26, 2017, the U.S. Court of Appeals for the Federal Circuit ruled in favor of Cumberland in a patent case associated with its Acetadote® product. Cumberland developed, registered, and launched Acetadote, which is now a standard of care for the leading cause of poisoning in the U.S.  The patent that was challenged has claims associated with Cumberland's next-generation formulation of Acetadote that is free of EDTA or any other preservative, chelating, or stabilizing agent.

  • PR Newswirelast month

    Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors

    NASHVILLE, Tenn., Jan. 16, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) is pleased to announce the addition of Kenneth J. Krogulski, CFA to its Board of Directors. Mr. Krogulski has over 37 years' experience in security analysis and portfolio management.